scholarly journals Measurement of the Total Lung Volume Using an Adjusted Single-Breath Helium Dilution Method in Patients With Obstructive Lung Disease

2021 ◽  
Vol 8 ◽  
Author(s):  
Qing Liu ◽  
Lingxiao Zhou ◽  
Peiling Feng ◽  
Jinkai Liu ◽  
Bin Shen ◽  
...  
Keyword(s):  
Lung Disease ◽  
Lung Volume ◽  
Obstructive Lung Disease ◽  
Validation Cohort ◽  
Training Group ◽  
Whole Body ◽  
Dilution Method ◽  
Total Lung Volume ◽  
Single Breath ◽  
Helium Dilution

Background: Whole-body plethysmography (WBP) is the gold standard for measuring lung volume, but its clinical application is limited as it requires expensive equipment and is not simple to use. Studies have shown that the single-breath helium dilution (SBHD) method, which is commonly used in clinical practice, significantly underestimates lung volume in patients with obstructive lung disease (OLD). By comparing the differences in lung volume measured using SBHD and WBP, we aimed to establish a correction equation for the SBHD method to determine the total lung volume in patients with OLD of different severities.Methods: From 628 patients with OLD simultaneously subjected to SBHD and WBP, 407 patients enrolled between January 2018 and November 2019 were in the training group and 221 enrolled between December 2019 and December 2020 were in the prospective verification cohort. The multiple linear regression equation was used for data in the training group to establish a correction equation for SBHD to determine the total lung volume, and this was validated in the prospective validation cohort.Results: There was a moderate positive correlation between total lung capacity (TLC) determined using the SBHD [TLC (SBHD)] and WBP methods [TLC (WBP)] (r = 0.701; P < 0.05), and the differences between TLC (SBHD) and TLC (WBP) (ΔTLC) were related to the severity of obstruction. As the severity of obstruction increased, the TLC was underestimated by the SBHD method. We established the following correction equation: TLC (adjusted SBHD) (L) = −0.669 + 0.756*TLC(SBHD)(L) – 0.047*FEV1FVC+0.039*height (cm)–0.009*weight(kg)(r2 = 0.753 and adjusted r2 = 0.751). Next, we validated this equation in the validation cohort. With the correction equation, no statistical difference was observed between TLC (adjusted SBHD) and TLC (WBP) among the obstruction degree groups (P > 0.05).Conclusions: The SBHD method is correlated with WBP to measure the total lung volume, but the SBHD method presents limitations in determining the total lung volume in patients with obstructive lung disease. Here, we established an effective and reliable correction equation in order to accurately assess the total lung volume of patients with OLD using the SBHD method.

Flow-Volume Curves in Infants with Lung Disease

PEDIATRICS ◽  
1983 ◽  
Vol 72 (4) ◽  
pp. 517-522
Author(s):  
S. Godfrey ◽  
E. Bar-Yishay ◽  
I. Arad ◽  
L. I. Landau ◽  
L. M. Taussig
Keyword(s):  
Lung Disease ◽  
Airway Obstruction ◽  
Lung Volume ◽  
Airway Resistance ◽  
Whole Body ◽  
Small Airways ◽  
Forced Expiration ◽  
Flow Volume ◽  
Complete Evaluation ◽  
Expiratory Flow

Partial expiratory flow-volume maneuvers have been performed on nine occasions on six infants with a variety of pulmonary problems using a new tech nique for thoracic compression. The infants were placed within an inflatable bag that was, itself, within a canvas bag. By sudden controlled inflation of the inner bag at end inspiration, partial expiratory flow-volume curves were generated and recorded by means of a face mask and pneumotachograph. By comparing these flow results with those airway resistance and lung volume measurements obtained from the infants in whole body plethysmography and by noting the effect of inhaling a helium/oxygen gas mixture, it was possible to partition the airway obstruction between large and small airways. The presence of small airway obstruction was noted in the absence of changes in airway resistance or lung volume in several instances. A complete evaluation of airway function should include this test of forced expiration for greater understanding and treatment of lung disease in infancy.

scholarly journals Assessment of lung volume collapsibility in chronic obstructive lung disease patients using CT

2013 ◽  
Vol 23 (6) ◽  
pp. 1564-1572 ◽  
Author(s):  
Shinjini Kundu ◽  
Suicheng Gu ◽  
Joseph K. Leader ◽  
John R. Tedrow ◽  
Frank C. Sciurba ◽  
...  
Keyword(s):  
Lung Disease ◽  
Lung Volume ◽  
Obstructive Lung Disease ◽  
Chronic Obstructive Lung Disease ◽  
Chronic Obstructive

scholarly journals Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female Mice

Endocrinology ◽  
2013 ◽  
Vol 154 (12) ◽  
pp. 4503-4511 ◽  
Author(s):  
Niels-Erik Viby ◽  
Marie S. Isidor ◽  
Katrine B. Buggeskov ◽  
Steen S. Poulsen ◽  
Jacob B. Hansen ◽  
...  
Keyword(s):  
Lung Function ◽  
Lung Disease ◽  
Obstructive Lung Disease ◽  
Whole Body ◽  
Control Group ◽  
Chronic Obstructive ◽  
Mrna Levels ◽  
Female Mice ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogs are used for the treatment of type 2 diabetes. GLP-1 displays antiinflammatory and surfactant-releasing effects. Thus, we hypothesize that treatment with GLP-1 analogs will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with a measurement of enhanced pause in a whole-body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Enhanced pause increased dramatically at day 17 in all control mice, but the increase was significantly less in the groups of GLP-1R agonist-treated mice (P < .001). Survival proportions were significantly increased in GLP-1R agonist-treated mice (P < .01). SFTPB and SFTPA were down-regulated and the expression of inflammatory cytokines were increased in mice with obstructive lung disease, but levels were largely unaffected by GLP-1R agonist treatment. These results show that GLP-1R agonists have potential therapeutic potential in the treatment of obstructive pulmonary diseases, such as chronic obstructive pulmonary disease, by decreasing the severity of acute exacerbations. The mechanism of action does not seem to be the modulation of inflammation and SFTP expression.

scholarly journals Effect of Whole Body Vibration on Exercise Capacity and Quality ofLife in Obstructive Lung Disease

2021 ◽  
Vol 89 (3) ◽  
pp. 47-52
Author(s):  
WEAAM S. HASANEEN, M.Sc.; SAMIR A. ALGAZZAR, Ph.D. ◽  
EMAN R. EL-ADAWY, M.D.; SAIFELDEEN A. RAGAB, Ph.D.*
Keyword(s):  
Lung Disease ◽  
Exercise Capacity ◽  
Obstructive Lung Disease ◽  
Whole Body Vibration ◽  
Whole Body ◽  
Quality Oflife ◽  
Body Vibration

Effects of Whole Body Vibration in Patients with Chronic Obstructive Lung Disease

2018 ◽  
pp. 133-150
Author(s):  
Dulciane N. Paiva ◽  
Patrícia E. M. Marinho ◽  
Litiele E. Wagner ◽  
Marciele S. Hopp ◽  
Armèle Dornelas de Andrade
Keyword(s):  
Lung Disease ◽  
Obstructive Lung Disease ◽  
Whole Body Vibration ◽  
Chronic Obstructive Lung Disease ◽  
Whole Body ◽  
Chronic Obstructive ◽  
Body Vibration

Reassessment of the interruption technique for measuring flow resistance in humans

1989 ◽  
Vol 67 (3) ◽  
pp. 933-937 ◽  
Author(s):  
G. Liistro ◽  
D. Stanescu ◽  
D. Rodenstein ◽  
C. Veriter
Keyword(s):  
Lung Disease ◽  
Healthy Subjects ◽  
Obstructive Lung Disease ◽  
Airflow Obstruction ◽  
Forced Expiratory Volume ◽  
Whole Body ◽  
Quiet Breathing ◽  
Flow Interruption ◽  
Whole Body Plethysmography ◽  
Closed Airway

We have previously produced evidence that, in patients with obstructive lung disease, compliance of extrathoracic airways is responsible for lack of mouth-to-alveolar pressure equilibration during respiratory efforts against a closed airway. The flow interruption method for measuring respiratory resistance (Rint) is potentially faced with the same problems. We reassessed the merits of the interruption technique by rendering the extrathoracic airways more rigid and by using a rapid shutter. We measured airway resistance (Raw) with whole body plethysmography during panting (at 2 Hz) and Rint during quiet breathing. Rint and Raw were expressed as specific airway (sGaw) and interruptive conductance (sGint), respectively. In nine healthy subjects (cheeks supported), sGint (0.140 +/- 0.050 s-1.cmH2O-1) was lower (P less than 0.02) than sGaw (0.182 +/- 0.043 s-1.cmH2O-1). By contrast, in 12 patients with severe obstructive lung disease (forced expiratory volume in 1 s/vital capacity = 41.0 +/- 19.8%), sGint (0.058 +/- 0.012 s-1.cmH2O-1) was higher (P less than 0.05) than sGaw (0.047 +/- 0.007 s-1.cmH2O-1), when the cheeks were supported. When the mouth floor was also supported, average values of sGaw (0.048 +/- 0.008 s-1.cmH2O-1) and sGint (0.049 +/- 0.014 s-1.cmH2O-1) became similar. In conclusion, we confirm previous findings in healthy subjects of higher values of Rint, with respect to Raw, probably because of differences in glottis opening between quiet breathing and panting. In airflow obstruction, supporting both the cheeks and the mouth floor decreased sGint, which became similar to sGaw.

Sign in / Sign up

Export Citation Format

Share Document